NERV logo

NERVMinerva Neurosciences Inc

$4.25
$0.43
(9.19%)
Pre-Market
Updated: 08:03 AM EDT·Prev Close $4.68
Reported EarningsMay 5
Mkt Cap$218.04M
Vol14.00
News
all
press releases
All You Need to Know About Minerva Neurosciences (NERV) Rating Upgrade to Buy
Minerva Neurosciences (NERV) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Zacks
News Placeholder
More News
News Placeholder
Minerva Neurosciences (NERV) Loses 37.5% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
The heavy selling pressure might have exhausted for Minerva Neurosciences (NERV) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Zacks
News Placeholder
Minerva Neurosciences (NASDAQ:NERV) Posts Quarterly Earnings Results, Misses Expectations By $0.04 EPS
Minerva Neurosciences (NASDAQ:NERV - Get Free Report) released its quarterly earnings data on Tuesday. The biopharmaceutical company reported ($0.17) earnings per share (EPS) for the quarter, missing...
MarketBeat
News Placeholder
Minerva Neurosciences, Inc (NASDAQ:NERV) Short Interest Update
Minerva Neurosciences, Inc (NASDAQ:NERV - Get Free Report) was the target of a significant increase in short interest during the month of April. As of April 15th, there was short interest totaling...
MarketBeat
News Placeholder
Minerva Neurosciences (NASDAQ:NERV) Now Covered by Citizens Jmp
Citizens Jmp began coverage on Minerva Neurosciences in a report on Wednesday. They set an "outperform" rating and a $14.00 target price for the company...
MarketBeat
News Placeholder
Minerva Neurosciences, Inc (NASDAQ:NERV) Sees Significant Growth in Short Interest
Minerva Neurosciences, Inc (NASDAQ:NERV - Get Free Report) was the target of a large increase in short interest in the month of March. As of March 31st, there was short interest totaling 1,020,925...
MarketBeat
News Placeholder
Minerva Neurosciences (NASDAQ:NERV) Shares Cross Below Fifty Day Moving Average - Should You Sell?
Minerva Neurosciences (NASDAQ:NERV) Stock Passes Below Fifty Day Moving Average - Here's What Happened...
MarketBeat
News Placeholder
Short Interest in Minerva Neurosciences, Inc (NASDAQ:NERV) Grows By 27.8%
Minerva Neurosciences, Inc (NASDAQ:NERV - Get Free Report) saw a significant growth in short interest in March. As of March 13th, there was short interest totaling 559,530 shares, a growth of 27.8...
MarketBeat
News Placeholder
Minerva Neurosciences Touts Roluperidone Data, FDA-Aligned Trial Plan for Schizophrenia Symptoms
Minerva Neurosciences (NASDAQ:NERV) provided an update on its development program for roluperidone, which the company described as a potential first treatment option aimed at the negative symptoms of...
MarketBeat
News Placeholder
HC Wainwright Has Bullish Forecast for NERV Q1 Earnings
Minerva Neurosciences, Inc (NASDAQ:NERV - Free Report) - Equities research analysts at HC Wainwright increased their Q1 2026 earnings per share (EPS) estimates for shares of Minerva Neurosciences in...
MarketBeat
<
1
2
...
>